Article abstract
Nature Immunology 10, 778 - 785 (2009)
Published online: 31 May 2009 | doi:10.1038/ni.1741
Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus
Agnès Doreau1,2,3, Alexandre Belot1,4,5,16, Jérémy Bastid1,6,7,16, Benjamin Riche1,8, Marie-Claude Trescol-Biemont1,2,3, Bruno Ranchin1,4, Nicole Fabien1,2,9, Pierre Cochat1,4,10, Claire Pouteil-Noble1,11, Pierre Trolliet1,11, Isabelle Durieu1,12, Jacques Tebib1,13, Berhouz Kassai1,14, Stéphane Ansieau1,6,7, Alain Puisieux1,6,7, Jean-François Eliaou15 & Nathalie Bonnefoy-Bérard1,2,3
Abstract
Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established. Here we demonstrate that IL-17 alone or in combination with B cell–activating factor controlled the survival and proliferation of human B cells and their differentiation into immunoglobulin-secreting cells. This effect was mediated mainly through the nuclear factor-
B-regulated transcription factor Twist-1. In support of the relevance of our observations and the potential involvement of IL-17 in B cell biology, we found that the serum of patients with systemic lupus erythematosus had higher concentrations of IL-17 than did the serum of healthy people and that IL-17 abundance correlated with the disease severity of systemic lupus erythematosus.
- Université de Lyon, Lyon, France.
- Institut National de la Santé et de la Recherche Médicale (INSERM) U851, Lyon, France.
- Université Lyon 1, Institut Fédératif de Recherche 128, Lyon, France.
- Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hôpital Femme Mère Enfant, Bron, France.
- Centre National de la Recherche Scientifique, UMR5239, Oullins, France.
- INSERM U590, Lyon, France.
- Centre Léon Bérard, Fédération Nationale des Centres de Lutte Contre le Cancer, Lyon, France.
- Service de Biostatistique, Lyon, France.
- Service d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.
- INSERM U820, Lyon, France.
- Service de Néphrologie, Lyon, France.
- Service de Médecine Interne, Lyon, France.
- Service de Rhumatologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.
- Service de Pharmacologie Clinique, Hôpital L.-Pradel, INSERM CIC201, Epidémiologie Pharmacologie Investigation Clinique Information Médicale Mère-Enfant, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5558, Centre Hospitalier Universitaire de Lyon, Lyon, France.
- Service d'Immunologie, Centre Hospitalier Universitaire de Montpellier, Faculté de Médecine; Université Montpellier 1, Montpellier, France.
- These authors contributed equally to this work.
Correspondence to: Nathalie Bonnefoy-Bérard1,2,3 e-mail: nathalie.bonnefoy-berard@inserm.fr
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
BLySsful interactions between DCs and B cellsNature Immunology News and Views (01 Sep 2002)
Gatekeeper mechanisms for immature B cellsNature Immunology News and Views (01 Oct 2002)
See all 4 matches for News And ViewsRESEARCH
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990?1999Bone Marrow Transplantation Original Article
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology Article (01 Sep 2002)
See all 29 matches for Research
